The regulator said its approval of groundbreaking Rimegepant marks a 'step-change in treatment' for the 'invisible disability that affects all aspects of life'
Marketing authorisation for AbbVie s Aquipta pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
The new treatment is a type of medication called a CGRP inhibitor, which blocks the effect of calcitonin gene-related peptide - a protein known to trigger debilitating migraines.